Arrowhead Pharmaceuticals已向监管机构申请许可,计划启动其药物Aro-Mapt用于治疗阿尔茨海默病及其他tau蛋白病的1/2a期临床研究。
Arrowhead Pharmaceuticals已向监管机构申请许可,计划启动其药物Aro-Mapt用于治疗阿尔茨海默病及其他tau蛋白病的1/2a期临床研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.